Association of interleukin-1 beta (-511C/T) polymorphisms with osteoporosis in postmenopausal women

Annals of Saudi Medicine

Volumn 30, Issue 6, 2010, Pages

  Chao, Tai Hung ^a   Yu, Hsing Ning ^a   Huang, Chi Chuan ^a   Liu, Wen Shen ^b   Tsai, Ya Wen ^b   Wu, Wen Tung ^c  

^a ZUOYING ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b Asia Pacific Biotech Developing Inc   (Taiwan)

^c YUNG TA INSTITUTE OF TECHNOLOGY AND COMMERCE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA;

ADULT; AGED; ARTICLE; BASE PAIRING; BONE DENSITY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; INTRON; MAJOR CLINICAL STUDY; PATHOGENESIS; POLYMERASE CHAIN REACTION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; TAIWAN; VARIABLE NUMBER OF TANDEM REPEAT;

AGED; CHOLESTEROL; FEMALE; GENOTYPE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TAIWAN; TRIGLYCERIDES;

EID: 78649341357     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.4103/0256-4947.71062     Document Type: Article

References (32)

1. Stewart TL, Ralston SH. Role of genetic factors in the pathogenesis of osteoporosis. J Endocrinol 2000;166:235-45.
2. Ralston SH, de Crombrugghe B. Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev 2006;20:2492-506.
3. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-9.
4. Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 1994;19:382-4.
5. Romas E, Martin TJ. Cytokines in the pathogenesis of osteoporosis. Osteoporos Int 1997;7: S47-3.
6. Steinkasserer A, Spurr NK, Cox S, Jeggo P, Sim RB. The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci. Genomics 1992;13:654-7.
7. Kim JG, Ku SY, Lim KS, Jee BC, Suh CS, Kim SH, et al. Cytokine production by whole blood cells: Relationship to interleukin gene polymorphism and bone mass. J Korean Med Sci 2005;20:1017-22.
8. Di Giovine FS, Takhsh E, Blakemore AI, Duff GW. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet 1992;1:450.
9. Al Moundhri MS, Al Nabhani M, Al Bahrani B, Burney IA, Al Madhani A, Ganguly SS, et al. Interleukin-1beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms and gastric cancer risk in an Omani Arab population. Gastric Cancer 2006;9:284-90.
10. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993;91:403-4.
11. Bajnok E, Takacs I, Vargha P, Speer G, Nagy Z, Lakatos P. Lack of association between interleukin-1 receptor antagonist protein gene polymorphism and bone mineral density in Hungarian postmenopausal women. Bone 2000;27:559-62.
12. Langdahl BL, Lokke E, Carsyens M, Stenker LL, Eriksen EF. Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1-receptor antagonist gene but not with polymorphism in the interleukin-1-gene. J Bone Miner Res 2000;15:402-14.
13. Nemetz A, Toth M, Garcia-Gonzalez MA, Zagoni T, Fecher J, Pena AS, et al. Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut 2001;49:644-9.
14. Chen HY, Chen WC, Wu MC, Tsai FJ, Lin CC. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphism in postmenopausal women: Correlation to bone mineral density and susceptibility to osteoporosis. Maturitas 2003;44:49-54.
15. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
16. Kröger H, Laitinen K. Bone mineral density measured by dual-energy X-ray absorptiometry in normal men. Eur J Clin Invest 1992;22:454-60.
17. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell J P, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic value. Circulation 2002;105:2660-5.
18. Kha HT, Basseri B, Shouhed D, Richardson J, Tetradis S, Hahn TJ, et al. Oxysterols regulate differentiation of mesenchymal stem cells: Pro-bone and anti-fat. J Bone Miner Res 2004;19:830-40.
19. Brownbill RA, Ilich JZ. Lipid profile and bone paradox: Higher serum lipids are associated with higher bone mineral Density in postmenopausal women. J Womens Health (Larchmt) 2006;15:261-70.
20. Dennison EM, Syddall HE, Aihie Sayer A, Martin HJ, Cooper C, Hertfordshire Cohort Study Group. Lipid profile, obesity and bone mineral density: The Hertfordshire Cohort Study. QJM 2007;100:297-303.
21. Broulik PD, Kapitola J. Interrelations between body weight, cigarette smoking and spine mineral density in osteoporotic Czech women. Endocr Regul 1993;27:57-60.
22. D'Amelio P, Pescarmona G P, Gariboldi A, Isaia GC. High density lioprotein (HDL) in women with postmenopausal osteoporosis: A preliminary study. Menopause 2001;8:429-32.
23. Samelson EJ, Cupples LA, Hannan MT, Wilson PW, Williams SA, Vaccarino V, et al. Long-term effects of serum cholesterol on bone mineral density in women and men: The Framingham Osteoporosis Study. Bone 2004;34:557-61.
24. Arai H, Miyamoto KI, Yoshida M, Yamamoto H, Taketani Y, Morita K, et al. The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J Bone Miner Res 2001;16:1256-64.
25. Albagha OM, Pettersson U, Stewart A, Mc-Guigan FE, MacDonald HM, Reid DM, et al. Association of oestrogen receptor apha gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone. J Med Genet 2005;42:240-6.
26. Keen RW, Woodford-Richens KL, Lanchbury JS, Spector TD. Allelic variation at the interleukin-1 receptor antagonist gene is associated with early postmenopausal bone loss at the spine. Bone 1998;23:367-71.
27. Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the transforming growth factor -1 gene and osteoporosis. Bone 2003;32:297-310.
28. Hustmyer FG, Wallker E, Yu X P, Girasole G, Sakagami Y, Peacock M, et al. Cytokine production and surface antigen expression by peripheral blood mononuclear cells in postmenopausal osteoporosis. J Bone Miner Res 1993;8:51-9.
29. Pacifici R, Rifas L, Teitelbaum S, Slatopolsky E, McCracken R, Bergfeld M, et al. Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. Proc Natl Acad Sci U S A 1987;84:4616-20.
30. Zarrabeitia MT, Riancho JA, Amado JA, Napal J, Gonzalez-Macias J. Cytokine production by peripheral blood cells in postmenopausal osteoporosis. Bone Miner 1991;14:161-7.
31. Kim JG, Lim KS, Ku SY, Kim SH, Choi YM, Moon SY. Relations between interleukin-1, its receptor antagonist gene polymorphism, and bone mineral density in postmenopausal Korean women. J Bone Miner Metab 2006;24:53-7.
32. Riener EK, Keck C, Worda C, Hefler LA, Tempfer CB. Body mass index but not a polymorphism of the interleukin-1 receptor antagonist (IL-1 RA) gene is associated with age at natural menopause. Gynecol Obstet Invest 2004;58:117-20.